Singapore markets close in 4 hours 29 minutes

Takeda Pharmaceutical Company Limited (TAK)

NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
13.82-0.04 (-0.29%)
At close: 4:00PM EDT
Sign in to post a message.
  • j
    john s
    Takeda spent $90 billion buying Shire and Baxalta. Takeda now has a market cap of $45B + $38B in debt. This means Takeda's pre-merger business is valued at zero. Time for spin offs and restructuring.
  • M
    Michael
    Only one Analyst is following TAK. Earning estimates have been reduced by 50% from 2020 to 2022 to $0.59 for 2022 . TAK has not repurchased any shares for years. There is no reason to buy and hold TAK until management becomes investor friendly, repurchases shares and sells none performing products.
  • D
    Doug
    Excellent acqusition to further growth
  • A
    Arrowhead2019
    Sorry guys…I bought so it was destined to go down despite the new potential approval….
  • A
    Anonymous
    I bought in at 18.40 several months ago and this stock has been a dog ever since.
  • A
    A
    It shouldn't surprise anyone if Takeda, at today's price, is the Big Pharma Buy of the Decade. Really. Mgt. have delivered on promises made as it relates to reducing debt. Whether everything that got pared away in the process should have been remains to be seen.
    The company has a large portfolio of profitable treatments; it has an adequate pipeline; it has the support of the Bank of Japan and the Japanese economy; it has positioned itself to be China-facing from a strongly established American and European sales territory.
    It will continue to pay a big, fat, dividend and, while I would love to see it drop to USD twelve per share, the US$14.00 share price is ludicrous.
  • C
    Coolmask
    Cathie wood big bagholder bought around $17-18 from last year. And then she sold at a loss at $14
  • A
    Adam
    in the tank for over 30k
  • D
    David
    Lowest price for almost a year - late Oct-early Nov, when it dipped down into the $15’s. Buying opportunity or a falling Samurai Knife?
  • n
    nobodyknows
    TAK cooperates with Moderna on covid vax distribution, but PFE is less problematic, so more popular (including Japan).
  • D
    Doug
    Almost 6 percent yield with the largest pharma in Japan, and growing with many disruptive pipelines and drug. It is amazingly cheap at 12 P/E. If i compound the dividend, i will have 50% return in 7 years. The capital gain will be the bonus on top.
  • D
    David
    How low can it go?
  • M
    MattK
    This stock just had an FDA approval yesterday .. no price jump, no messages, no company news, nothing. Is this normal behavior for this stock?
  • J
    John
    I sold all the last time it was over $19.40 then bought some back at $16.40 and again sold all at $17.00.
    I didn’t sell because of TAK I sold everything I could to grow my EPD holdings. Now I am going back around to
    prepare for investing some significant dividends/distributions in November. I am surprised by the price,
    Almost every thing I sold is down, just dumb luck on my part to sell.
    EPD was my major stagflation move starting the first of the year and I moved heavy into it and other
    MLP’S to the point that I abandoned the diversification maxim completely.
    I am probably going to add small amounts in multiple companies that have fallen significantly. I have about
    three weeks to think.
    Normally I would just buy, but the stagflation is accelerating and I know how mean and nasty it can get.
    Will be observing for now.
    Best Luck to All
    John
  • j
    john s
    If TAk comes out with cure for Covid how much is the stock worth $56?
  • J
    Jim
    They are running for the hills on this...vol exploded to the downside.
    Like I said, time for new management.
    Sad!!!!
  • K
    KF
    PE is 11...It makes money and has a dividend...Maybe when growth pharma resumes growth this will follow. ARK funds used to hold TAK. It is no longer in their portfolios.
  • n
    nobodyknows
    hope TAK gamble works, but hold puts, just in case.......
  • P
    PHILIP
    This time we won one.

    Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") today announced the U.S. Food and Drug Administration (FDA) Antimicrobial Drugs Advisory Committee (AMDAC) voted unanimously to recommend use of maribavir (TAK-620) for the treatment of refractory cytomegalovirus (CMV) infection and disease with genotypic resistance to ganciclovir, valganciclovir, foscarnet or cidofovir in transplant recipients. The committee also voted unanimously to recommend use of maribavir for the treatment of refractory CMV infection and disease without genotypic resistance to ganciclovir, valganciclovir, foscarnet or cidofovir in transplant recipients. Both recommendations were based on the results of the Phase 2 and Phase 3 TAK-620-303 (SOLSTICE) trials.

    "Today’s vote in favor of our investigational antiviral drug marks a significant step towards delivering the first approved treatment for adult transplant recipients with refractory CMV infection and disease, with or without resistance," said Obi Umeh, MD, Vice President and Maribavir Global Program Leader at Takeda. "We look forward to working with the FDA as it completes its review of our application."

    AMDAC also heard from patients, advocates, and healthcare providers in the public forum discussion who underscored the need for new treatment options for this patient population.

    The New Drug Application (NDA) for maribavir is currently under Priority Review by the FDA. The FDA will consider the vote as part of its review of the NDA and is not bound by the AMDAC’s recommendation. The NDA submission is based on the pivotal Phase 3 TAK-620-303 (SOLSTICE) trial.

    "The treatment of CMV in patients who have undergone a solid organ or stem cell transplant is complicated, especially in patients who have failed standard treatment and who may be at risk for side effects from currently available medications," said Dr. Emily Blumberg, Director, Transplant Infectious Diseases, Penn Medicine. "I am excited about the potential for an additional treatment option for post-transplant patients with CMV."

    You will have to read the whole release if you want all the info. Too long to post.
  • D
    DanielK
    Ugh. Down 6% in Japan.